NO20042361L - Form av 3-[(2{4-(Heksyloksykarbonylamino-imino-metyl)-fenylami no]-metyl}-1- metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral - Google Patents

Form av 3-[(2{4-(Heksyloksykarbonylamino-imino-metyl)-fenylami no]-metyl}-1- metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral

Info

Publication number
NO20042361L
NO20042361L NO20042361A NO20042361A NO20042361L NO 20042361 L NO20042361 L NO 20042361L NO 20042361 A NO20042361 A NO 20042361A NO 20042361 A NO20042361 A NO 20042361A NO 20042361 L NO20042361 L NO 20042361L
Authority
NO
Norway
Prior art keywords
methyl
hexyloxycarbonylamino
phenylamino
benzimidazole
imino
Prior art date
Application number
NO20042361A
Other languages
English (en)
Other versions
NO326918B1 (no
NO20042361D0 (no
Inventor
Norbert Hauel
Ulrich Brauns
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27789735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042361(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10209985A external-priority patent/DE10209985A1/de
Priority claimed from DE2002145624 external-priority patent/DE10245624A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20042361L publication Critical patent/NO20042361L/no
Publication of NO20042361D0 publication Critical patent/NO20042361D0/no
Publication of NO326918B1 publication Critical patent/NO326918B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår en ny administreringsform for oral anvendelse av den aktive substans etyl-3-[(2-{[4-(heksyloksykarbonylamino-imino-metyl)-fenylamino]-metyl}-1 -metyl-1 H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionat og de farmakologisk akseptable salter derav.
NO20042361A 2002-03-07 2004-06-07 Farmasoytisk preparat og fremgangsmate for fremstilling derav. NO326918B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10209985A DE10209985A1 (de) 2002-03-07 2002-03-07 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
DE2002145624 DE10245624A1 (de) 2002-09-30 2002-09-30 Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
PCT/EP2003/002141 WO2003074056A1 (de) 2002-03-07 2003-03-03 Oral zu applizierende darreichungsform für 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen salze

Publications (3)

Publication Number Publication Date
NO20042361L true NO20042361L (no) 2004-06-07
NO20042361D0 NO20042361D0 (no) 2004-06-07
NO326918B1 NO326918B1 (no) 2009-03-16

Family

ID=27789735

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20042361A NO326918B1 (no) 2002-03-07 2004-06-07 Farmasoytisk preparat og fremgangsmate for fremstilling derav.
NO20081304A NO332209B1 (no) 2002-03-07 2008-03-12 Etyl-3-[(2-{[4-(heksyloksykarbonyl¬amino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]-propionat- metansulfonat
NO2013001C NO2013001I2 (no) 2002-03-07 2013-01-02 Dabigatran-etexilate og salter derav; spesielt dabigatran-etexilate-mesylate

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20081304A NO332209B1 (no) 2002-03-07 2008-03-12 Etyl-3-[(2-{[4-(heksyloksykarbonyl¬amino-imino-metyl)-fenylamino]-metyl}-1-metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]-propionat- metansulfonat
NO2013001C NO2013001I2 (no) 2002-03-07 2013-01-02 Dabigatran-etexilate og salter derav; spesielt dabigatran-etexilate-mesylate

Country Status (35)

Country Link
US (2) US20190231766A1 (no)
EP (2) EP1870100B1 (no)
JP (3) JP3866715B2 (no)
KR (1) KR101005716B1 (no)
CN (1) CN100528157C (no)
AR (2) AR042861A1 (no)
AT (1) ATE540943T1 (no)
AU (1) AU2003210400B8 (no)
BR (1) BRPI0306559B8 (no)
CA (1) CA2476054C (no)
CL (1) CL2009001915A1 (no)
CO (1) CO5611149A2 (no)
CY (4) CY1112796T1 (no)
DE (1) DE122012000047I1 (no)
DK (2) DK1870100T3 (no)
EA (1) EA009664B1 (no)
EC (1) ECSP045331A (no)
ES (2) ES2380704T3 (no)
HR (1) HRP20040807B1 (no)
IL (3) IL163863A0 (no)
LU (2) LU92025I2 (no)
ME (1) ME00325B (no)
MX (1) MXPA04008542A (no)
MY (1) MY143734A (no)
NO (3) NO326918B1 (no)
NZ (2) NZ546367A (no)
PE (1) PE20030889A1 (no)
PL (2) PL212566B1 (no)
PT (2) PT1485094E (no)
RS (1) RS52088B (no)
SG (1) SG146435A1 (no)
SI (2) SI1870100T1 (no)
TW (1) TWI293879B (no)
WO (1) WO2003074056A1 (no)
ZA (1) ZA200406071B (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE10341043A1 (de) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
JPWO2005113010A1 (ja) * 2004-05-24 2008-07-31 クオリカプス株式会社 表面改質および溶解性が改善された硬カプセル
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
CA2657270A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New paediatric indications for direct thrombin inhibitors
EA200900091A1 (ru) * 2006-07-17 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
CA2716642C (en) 2008-03-28 2017-02-28 Boehringer Ingelheim International Gmbh Method for manufacturing acid pellets
RU2010143901A (ru) * 2008-03-28 2012-05-10 Бёрингер Ингельхайм Интернациональ Гмбх (De) Способ получения композиций дабигатрана для перорального введения
AR072557A1 (es) * 2008-07-14 2010-09-08 Boehringer Ingelheim Int Proceso para preparar composiciones de medicamentos que contienen dabigatran
TW201010992A (en) 2008-07-28 2010-03-16 Takeda Pharmaceutical Pharmaceutical composition
WO2010020600A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
WO2010020602A1 (en) * 2008-08-19 2010-02-25 Boehringer Ingelheim International Gmbh Dabigatran for percutaneous interventional cardiac catheterisation
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
AR077909A1 (es) 2009-08-24 2011-09-28 Boehringer Ingelheim Int Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran
US20130052262A1 (en) * 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
EP2545044A1 (en) 2010-03-08 2013-01-16 ratiopharm GmbH Dabigatran etexilate-containing pharmaceutical composition
EP2588090B2 (en) 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012004397A1 (en) 2010-07-09 2012-01-12 Esteve Química, S.A. Intermediates and process for preparing a thrombin specific inhibitor
US8981105B2 (en) 2010-07-09 2015-03-17 Esteve Quimica, S.A. Process of preparing a thrombin specific inhibitor
ES2550771T3 (es) 2010-09-27 2015-11-12 Ratiopharm Gmbh Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CA2860098A1 (en) * 2011-12-22 2013-06-27 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
WO2013110567A1 (en) 2012-01-24 2013-08-01 Boehringer Ingelheim International Gmbh Novel orally administered dabigatran formulation
AU2013224146B2 (en) 2012-02-21 2017-06-08 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20150225370A1 (en) 2012-09-28 2015-08-13 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
WO2014049585A2 (en) 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
EP2722033A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
EP2722034B1 (en) 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2740471B1 (en) * 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
WO2015145462A1 (en) 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
WO2015155297A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
WO2015155281A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105764509B (zh) * 2014-11-03 2019-03-19 杭州领业医药科技有限公司 达比加群酯或其盐的投药制剂及其制备方法
CN105640909B (zh) * 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法
EP4205743A1 (en) 2014-12-31 2023-07-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition and preparation method therefor
CN106924256B (zh) * 2015-12-25 2022-08-19 深圳市药欣生物科技有限公司 药物组合物及其制备方法
TR201502223A2 (tr) 2015-02-25 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve dabigatranın farmasötik kombinasyonları.
CN106999434B (zh) * 2015-04-08 2020-05-22 杭州领业医药科技有限公司 一种含半胱氨酸盐酸盐的微丸及其制备方法
EP3324946A1 (en) 2015-07-20 2018-05-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations of dabigatran free base
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
EP3184102A1 (en) 2015-12-23 2017-06-28 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TR201606697A2 (tr) 2016-05-20 2017-12-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin yeni̇ oral farmasöti̇k formülasyonlari
WO2018104387A1 (en) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayered tablet compositions of dabigatran
TR201617984A2 (tr) 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
WO2018122262A1 (en) 2016-12-28 2018-07-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Bilayer tablet formulations of dabigatran etexilate
JP2018184375A (ja) 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
CN109125274A (zh) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 注射用苯并咪唑类药用酸组合物及其制备方法和用途
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722353A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722630A2 (no) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
KR20200082641A (ko) 2018-12-31 2020-07-08 주식회사 유영제약 다비가트란 에텍실레이트를 포함하는 약제학적 조성물
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
KR20210157692A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157693A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
KR20210157691A (ko) 2020-06-22 2021-12-29 한국유나이티드제약 주식회사 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN115227663B (zh) * 2021-04-22 2023-12-12 石药集团恩必普药业有限公司 一种甲磺酸达比加群酯胶囊及其制备方法
US20240366580A1 (en) * 2021-06-04 2024-11-07 Zim Laboratories Limited Novel pharmaceutical compositions comprising dabigatran etexilate or salt thereof
WO2023139243A1 (en) 2022-01-21 2023-07-27 Adamed Pharma S.A A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου
WO2024175037A1 (zh) * 2023-02-21 2024-08-29 广州玻思韬控释药业有限公司 达比加群酯或其药物可接受的盐的微丸
WO2024217830A1 (en) 2023-03-30 2024-10-24 Adamed Pharma S.A A process for preparation of hard capsules filled with dabigatran pellets

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) * 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
JP2005519099A (ja) 2005-06-30
SI1485094T2 (sl) 2020-08-31
AU2003210400B2 (en) 2008-08-07
NZ535663A (en) 2006-06-30
NO326918B1 (no) 2009-03-16
DK1485094T4 (da) 2020-06-22
PL394601A1 (pl) 2011-07-18
IL163863A0 (en) 2005-12-18
IL209368A0 (en) 2011-01-31
EP1485094B1 (de) 2012-07-04
PL210862B1 (pl) 2012-03-30
AU2003210400A1 (en) 2003-09-16
BR0306559A (pt) 2004-11-30
CY1113158T1 (el) 2015-08-05
HRP20040807B1 (hr) 2014-11-21
CN100528157C (zh) 2009-08-19
US20200085807A1 (en) 2020-03-19
EA009664B1 (ru) 2008-02-28
EP1870100B1 (de) 2012-01-11
CY2012031I2 (el) 2015-08-05
WO2003074056A1 (de) 2003-09-12
IL209368A (en) 2012-10-31
EP1485094A1 (de) 2004-12-15
NO20081304L (no) 2004-06-07
TW200306188A (en) 2003-11-16
CY2012031I1 (el) 2015-08-05
CN1638771A (zh) 2005-07-13
CY2012020I2 (el) 2015-08-05
JP2007056018A (ja) 2007-03-08
IL163863A (en) 2013-02-28
CO5611149A2 (es) 2006-02-28
PT1870100E (pt) 2012-04-17
BRPI0306559B8 (pt) 2021-05-25
ES2380704T3 (es) 2012-05-17
KR20040099298A (ko) 2004-11-26
PL370517A1 (en) 2005-05-30
EP1485094B2 (de) 2020-03-25
ES2380704T9 (es) 2013-07-24
JP3866715B2 (ja) 2007-01-10
NO2013001I1 (no) 2013-02-11
ATE540943T1 (de) 2012-01-15
BRPI0306559B1 (pt) 2021-05-18
KR101005716B1 (ko) 2011-01-05
CY1112796T1 (el) 2015-08-05
ME00325B (me) 2011-05-10
AU2003210400B8 (en) 2008-09-25
RS52088B (sr) 2012-06-30
TWI293879B (en) 2008-03-01
PL212566B1 (pl) 2012-10-31
CL2009001915A1 (es) 2010-02-12
LU92117I2 (fr) 2013-02-19
ES2390661T3 (es) 2012-11-15
NO2013001I2 (no) 2014-09-01
CY2012020I1 (el) 2015-08-05
AR072385A2 (es) 2010-08-25
NZ546367A (en) 2008-08-29
CA2476054A1 (en) 2003-09-12
ECSP045331A (es) 2006-04-19
SI1485094T1 (sl) 2012-10-30
PT1485094E (pt) 2012-10-09
US20190231766A1 (en) 2019-08-01
JP4953727B2 (ja) 2012-06-13
EP1870100A1 (de) 2007-12-26
NO20042361D0 (no) 2004-06-07
RS79204A (sr) 2007-02-05
ZA200406071B (en) 2005-11-30
AR042861A1 (es) 2005-07-06
DK1485094T3 (da) 2012-10-15
MEP50708A (en) 2011-02-10
DK1870100T3 (da) 2012-05-14
HRP20040807A2 (en) 2005-02-28
JP2006328081A (ja) 2006-12-07
EA200401136A1 (ru) 2005-04-28
ES2390661T5 (es) 2020-12-04
HK1078792A1 (en) 2006-03-24
MY143734A (en) 2011-07-15
SI1870100T1 (sl) 2012-05-31
NO332209B1 (no) 2012-07-30
DE122012000047I1 (de) 2012-09-13
SG146435A1 (en) 2008-10-30
MXPA04008542A (es) 2004-12-06
PE20030889A1 (es) 2003-12-10
LU92025I2 (fr) 2012-08-20
CA2476054C (en) 2011-11-08

Similar Documents

Publication Publication Date Title
NO20042361L (no) Form av 3-[(2{4-(Heksyloksykarbonylamino-imino-metyl)-fenylami no]-metyl}-1- metyl-1H-benzimidazol-5-karbonyl)-pyridin-2-yl-amino]propionsyreetylester for oral
CY1109299T1 (el) Μεθανοσουλφονικο αλας 3-[(2-{[4-εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1-μεθυλο-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλο-αμινο]-προπιονικου αιθυλεστερα και η χρηση αυτου ως φαρμακευτικο μεσο
NO20075862L (no) Polymorfer av etyl-3-[(2-{[4-(heksyloksykarbonylamino-iminometyl)fenylamino]metyl}-1-metyl-1H-benzimidazol-5-karbonyl)pyridin-2-ylamino]propionat
CY1108218T1 (el) Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα
NO20054852L (no) GFAT inhibitorer
WO2006114415A3 (de) Physiologisch verträgliche salze von 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
NO20052474L (no) Amort form av esomeprazolsalter
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
NO20021875D0 (no) Fremgangsmåte for stabilisering av benzimidazolforbindelser
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
NO20050771L (no) Bicifadinformulering
UA95601C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1метил-1н- бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и фармацевтическая композиция, которая его содержит
NO20055257L (no) Ny fremgangsmate for syntesen av s-indolin-2-karboksylsyre og anvendelse derav i syntesen av perindopril
NO20062599L (no) Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav
ITMI20040235A1 (it) Preparazione farmaceutica per il cavo orale
ATE228126T1 (de) 2- 4-(4-(4,5-dichlor-2-methylimidazol-1- yl)butyl)piperazin-1-yl -5-fluorpyrimidin, seine herstellung und therapeutische verwendung
DOP2002000517A (es) Sal de acido cintrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen.
NO20064112L (no) Farmasoytiske doseringsformer og preparater

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, DE

MK1K Patent expired